Pure Global

Single-ascending Dose Study of Kylo-11 in Healthy Subjects - Trial NCT06363851

Access comprehensive clinical trial information for NCT06363851 through Pure Global AI's free database. This Phase 1 trial is sponsored by Kylonova (Xiamen) Biopharma co., LTD. and is currently Not yet recruiting. The study focuses on Cardiovascular Diseases. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06363851
Phase 1
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06363851
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Single-ascending Dose Study of Kylo-11 in Healthy Subjects
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Kylo-11 in Healthy Subjects

Study Focus

Cardiovascular Diseases

Kylo-11

Interventional

drug

Sponsor & Location

Kylonova (Xiamen) Biopharma co., LTD.

Chengdu, China

Timeline & Enrollment

Phase 1

May 31, 2024

Nov 30, 2025

60 participants

Primary Outcome

Incidence of adverse events

Summary

This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose
 study in healthy volunteers. Kylo-11 will be evaluated in approximately 60 subjects to assess
 safety, tolerability, pharmacokinetics and pharmacodynamic effects.

ICD-10 Classifications

Cardiovascular disease, unspecified
Hypertensive heart disease
Other ill-defined heart diseases
Heart disease, unspecified
Observation for other suspected cardiovascular diseases

Data Source

ClinicalTrials.gov

NCT06363851

Non-Device Trial